Water-in-oil microemulsions for effective transdermal delivery of proteins

Gregory Russell-Jones & Roy Himes

Introduction: A water-in-oil microemulsion is a thermodynamically stable emulsion that has the capacity to ‘hide’ water-soluble molecules within a continuous oil phase. The very small size of the water droplets within the microemulsion means that these types of formulation can be applied topically to the skin, with the result that peptides and proteins can be delivered effectively into the dermal layer.

Areas covered: This review discusses the general problems of peptide and protein delivery following topical application, and compares the possible routes of peptide and protein clearance and distribution within the body following topical administration. Several examples of successful peptide and protein delivery using microemulsions are discussed, in addition to the possible alterations in biological profiles following administration via this route.

Expert opinion: Water-in-oil microemulsions present themselves as an effective means of topical delivery of peptides and proteins of all sizes, and in high doses. These formulations are a cheap, stable, pain-free means of delivery of peptides and proteins to the skin. An exciting area of potential development is the area of weight control management. The results using insulin, IGF-I and GHRP-6 given topically are particularly intriguing. Whether these results can be replicated in humans and whether the use of these drugs for potential treatment of obesity will be commercially viable will be particularly interesting.

Keywords: GHRP-6, IGF-I, insulin, microemulsion, transdermal, vaccine delivery, weight loss

1. Introduction

The skin is the largest organ in the body, and presents itself as a readily accessible site for administration of pharmaceutical products, particularly since there is a plethora of skin conditions, which could potentially benefit from local delivery. Transdermal drug delivery has been a commercial reality for over 40 years. The molecules delivered, however, have been restricted to small lipid-soluble molecules applied in a variety of devices, including patches, ointments, creams and gels. Molecules delivered include testosterone, oestradiol, scopalamine, fentanyl, diclofenac, nitroglycerin, clonidine, apomorphine, nicotine and various non-steroidal anti-inflammatory molecules, among others. A review of methods of delivery can be found in the article by Subedi et al. [1].

Many different methods of delivery have been developed for topical applications, including patches (Climira™, Minitran™ (3M, MN, USA)), thermoporation (Passport™ Apomorphine (Altea Therapeutics Corp., GA, USA)), reservoir patches (Duragesic™, (Alza Corp., MN, USA)), diffusive patches (Elestrin™, ATD™...
Transdermal delivery systems, such as reservoir and matrix-type patches, have been used in the development of several products for the delivery of low-molecular-mass and/or hydrophobic drugs such as clonidine, fentanyl, estradiol, testosterone, nitroglycerin, nicotine, scopolamine, oxybutinin and lidocaïne [17]. Although the transdermal delivery of these molecules has commercial and pharmaceutical validity in its own right, there are many disease applications that are treated with peptide or protein preparations, usually by means of injection, as they cannot be delivered via topical application at present.

Despite the barrier function of skin, small lipophilic molecules are easily administered through the skin, but it is difficult to administer water-soluble protein and peptide drugs that are on the market or under development.

When disruptive mechanisms such as electroporation have been used for protein delivery, they have shown an inverse relationship between size and transdermal transport [18]. These problems are exacerbated further in iontophoresis, which has been shown to be highly variable depending on conditions of solvent ions, cargo charge, pH and amperage applied [19].

Recently, however, a new delivery formulation has been described that overcomes most of the problems associated with transdermal peptide and protein delivery. This technology utilizes the ability of water-in-oil microemulsions effectively to ‘hide’ water-soluble molecules within an oil layer, which can then be used to ‘smuggle’ water-soluble molecules such as proteins and peptides though the epidermis into the dermal layer, in a similar fashion to the way in which ‘vanishing creams’ vanish when applied topically. Topical delivery of peptides and proteins using water-in-oil microemulsions is the topic of this review.

2. Advantages of topical delivery

Topical delivery has several obvious advantages when compared with either oral delivery or subcutaneous injection, including improved patient comfort, lack of needle-stick injuries, reduced pain, improved safety, possible site-directed delivery, controlled and continuous drug delivery, with the avoidance of sharp peaks in delivery profile, improved efficacy and fewer side effects [12,20], all of which should lead to an improvement of patient compliance, and ultimate drug efficacy. Also, it has been found that the biological/pharmaceutical activity of the applied pharmaceutical can be altered, particularly when peptides and proteins are applied topically. This new activity is discussed later.

2.1 Circulation in the skin

The skin is amply supplied with a rich vascular network of arteries and veins, which are involved in temperature regulation, nutrient supply to the skin and the supply of many immunocompetent cells. Topically applied peptides and proteins cannot enter the circulation in the skin as there is no basal-to-apical transport of such molecules through the vascular endothelium, and as such they must travel in the lymphatics in order ultimately to reach the circulation [21].
2.2 Lymphatic clearance

Several workers have shown that clearance of large molecules such as proteins and large sugars, when injected intradermally, is almost exclusively by means of lymph vessels [22-27]. Transit of material within the lymph vessels is relatively rapid and varies from ~ 1.5 to 10.2 cm/min [28]; however, movement of molecules that have not reached the lymph vessels appears to be quite a bit slower, and is more akin to radial diffusion. The radial diffusion pattern observed is very similar to that observed following intradermal injection of sensitizing antigen in hypersensitive mice [29] and also following topical application of various water-soluble agents to human skin [30,31]. Thus, the applied material appears to diffuse symmetrically by means of simple radial diffusion, in which the applied material persists for many hours. Thus, when diffusion is visualized using the water-soluble fluorescent molecule umbelliferone, formulated in a water-in-oil microemulsion and applied topically, there are obvious signs of lateral diffusion in the dermal layer, reaching ~ 5 cm after 6 h (Figure 1). In this instance there is no obvious sign of concentration of material within a draining lymph vessel, rather, diffusion appears lateral. Such diffusion would be dependent on the absence of specific receptors for the solute molecule. Thus, for allergens applied by intradermal injection, there is a concentration-dependent diffusion of allergen and subsequent mast cell activation, which is the basis of the standard skin test for allergen hypersensitivity (see Figure 2). These observations are also consistent with those seen in humans, where the majority of intradermally injected doses persists at the site of application for several hours [28], and ultimately drains from distal or proximal lymph nodes many centimeters from the site of injection [28,32-39].

2.3 Choice of models

Many skin permeation studies have been performed in vitro on sections of excised skin from various sources, including rat, pigs and humans. In many instances the skin could be regarded as rather less than live, having been prepared and frozen before defrosting and use [40,41]. One must question the relevance of these studies in light of the many observations of lateral diffusion of applied drug through the dermal layer of the skin, the lack of muscular movement in the chambers, plus the degree of pressure that is applied to the skin samples during their 'mounting' in the chambers. Even small amounts of pressure, such as that exerted by a sock on a human leg, can be sufficient to inhibit vascular drainage. As such it is questionable as to whether these 'clamped skin' models are representative of reality [28]. For the reasons outlined above, the studies reported here have been on live, conscious animals, or humans.

3. Transport across the dermal layer using microemulsions

There appears to be little evidence for topical delivery of peptides and proteins in water-based formulations. By contrast, there is now a growing body of evidence that oil-based formulations, more particularly water-in-oil microemulsions, may have the potential for the delivery of milligram quantities of peptides and even large proteins through the epidermal layer and into the dermis [30,31,42,43]. Microemulsions have enormous advantages in delivery because of their high solubilization capacity, ease of preparation, transparency, thermodynamic stability, and high diffusion and absorption rates [44,45]. The microemulsions are easily formed, and an excellent discussion on the theory and practice of microemulsions can be found in the publication edited by Prince [46]. Although it is not the object of this review to describe the methods for formation of microemulsions, the essential conditions for their formation have been described by authors such as Schulman et al. [47], Kumar and Mittal [48] and Constantinedes et al. [44].

Water-in-oil microemulsions have been shown to have a highly favorable drug delivery potential, which may be attributed to both their excellent solubility properties as well as the possible permeation enhancement through easy dispersion through the dermal lipids [49-51]. Most previous work, both in small animals and humans, has utilized microemulsions containing small hydrophobic molecules [52-55], or small 'model' hydrophilic molecules [64-66]. Often this work has been performed in chambers, rather than on live conscious animals [59,64,67]. The validity of these models in measuring lateral movement of topically applied material is rather questionable, and so data from these studies are not included in this review.

3.1 Peptide and protein delivery with microemulsions

There are only a few studies of transdermal peptide delivery using microemulsions. These studies describe delivery of small peptides such as desmopressin [68], cyclosporine [69] and the folate analogue methotrexate [49]. Although these studies do point to the potential utility of water-in-oil microemulsions for transdermal delivery of small water-soluble molecules, it has recently become evident that these microemulsions may have a much more generic role in the delivery of a wide range of water-soluble molecules, extending from small peptides (described above) to large proteins of 100 – 150,000 Da molecular mass [31,42,43]. In their studies, Russell-Jones and co-workers topically radiolabeled anti-TNF receptor Fc-fusion protein formulated in W/O ME to the shaved skin of conscious mice, and found that the label rapidly entered the dermal layer of the mouse skin, and subsequently moved laterally through the skin to distal areas of the skin, and muscle. The systemic bioavailability following topical administration was found to be > 50%, most of which (~ 70%) remained in the skin for > 4 h. During the time of the experiment there was no discernable evidence of breakdown of the topically applied molecules as evidenced by the lack of 125I counts detectable in the thyroid of the mice. By contrast, there was evidence of breakdown of orally administered antibodies, which could be measured by the presence of 125I counts in the thyroid and urine. The
bioactivity of the formulated proteins was found to be substantially maintained during formulation within the microemulsion and during transit through the skin, as judged by the ability of anti-TNF molecules such as Enbrel® (Amgen, USA), Remicade™ (Centocor, PA, USA), Humira™ (Abbott Labs, IL, USA); and the human cell-expressed TNF-RII molecule to reduce carrageenan-induced inflammation of the foot following topical administration in the W/O ME.

3.2 Use of microemulsions for topical vaccination

Delivery of protein antigens into the skin is perhaps one of the most desirable routes for vaccination. This is owing to the large number of dendritic cells resident in the dermal layer of the skin. These cells have previously been shown to have a major function in antigen presentation to the immune system [70]. Preliminary work has shown the effectiveness of transfersomes in stimulating an immune response following topical application of tetanus toxoid to rats [71]. More recently, the authors have shown that it is possible to formulate antigens such as tetanus toxoid within W/O ME and generate comparable antibody responses to that observed following subcutaneous injection (Table 1, Figure 3). The topical route of delivery in W/O ME was particularly good at generating good cellular immunity, which was found to be equal to or higher than intramuscular injection of antigen administered in adjuvant (Figure 3).

Interestingly for both the antibody response and the cellular response, complexation of tetanus toxoid with the adjuvant alum greatly reduced the subsequent immune response. This was presumably owing to complexation with the antigen, with resultant precipitation. It would be expected that this would prevent the oil-penetrating ability of the subsequent W/O ME.

3.3 Use of microemulsions for modification of obesity in mice

The studies outlined above have shown the utility of the water-in-oil microemulsions for transdermal delivery of peptides and proteins; however, they did not address whether there is any difference in the biological response seen when topically administered peptides were compared with the more traditional subcutaneous administration. It was therefore decided to compare the biological response with topical or subcutaneously administered peptide hormones. The first of these, insulin-like growth factor 1 (IGF-I), is an insulin-like molecule, which is an important factor in childhood growth and also in maintaining muscle mass in adults [72]. Also, it has been shown to have an effect in controlling obesity [73]. IGF-I is one of the main hormones released through the action of growth hormone [73], which in turn can be stimulated by the administration of several small peptide agonists, including growth hormone releasing hormone 6 (GHRP-6), which was also included as a comparator [74]. Insulin has also been shown to have an anabolic effect on muscle [75-78], but has been implicated in weight gain following subcutaneous administration to diabetic individuals, which is a result in part of its ability to stimulate differentiation of preadipocytes, and to increase the uptake of glucose into adipocytes and inhibit triglyceride breakdown [79-82]. It was therefore of interest to compare the effect of topical and subcutaneous administration of these three peptides in obese animals.

Outbred Swiss mice when kept on an ad lib diet of mouse chow have a tendency to become obese and may reach weights > 45 g (normal weight 25 g). Dissection of mice following euthanasia reveals obvious deposits of visceral fat (omental and mesenteric), subscapular fat and paired inguinal fat.
anabolic effect on the percentage muscle mass measured in treated animals when compared with control animals. By comparison, there was no increase in muscle mass in animals receiving these doses by means of subcutaneous injection. By contrast, all treatments (insulin, IGF-I and GHRP-6) had an effect on reducing the weight of adipose tissue, regardless of route. The greatest effect, however, was observed with topically applied insulin in a W/O ME (Figure 4A, B).

In a separate study, the effect of increasing the dose of topically administered insulin formulated in a water-in-oil microemulsion was compared with subcutaneously administered insulin. It was possible to increase the dose of topically administered insulin from 10 to 100 µg as there was no reduction in serum glucose seen at this dose (results not shown). By contrast, it was not possible to increase the dose of subcutaneously administered insulin owing to the potential of death through induction of hypoglycemia. As is normal for this strain of mice, the control animals gained weight during the experiment. By contrast, topical or subcutaneously administered insulin had a differing effect, which depended on the initial weight of the mice. Thus, those mice whose starting weight was > 30.0 g lost weight, with the largest weight loss observed with the mice that were heaviest at the start of the experiment and who received the highest dose of topical insulin (100 µg). By contrast, the mice whose starting weight was < 30 g gained weight, with the highest weight gain on the smallest mice given the highest dose of topical insulin (100 µg) (Figure 5). These data are consistent with the known anabolic effect of insulin [75-78] and possibly suggest receptor downregulation on adipocytes, with resultant breakdown of stored fats (lipolysis) [79-82]. Presumably the greater effect seen with the topical insulin is due to the depot-like effect of this route of administration, leading to a longer stimulation of both adipocytes and muscle cells.

### 4. Conclusion

Effective peptide and protein delivery to the skin has received much attention in the pharmaceutical industry, with many companies developing a variety of delivery devices to force peptides and proteins into and across the epithelium of the skin. Despite these many attempts, effective delivery of high-molecular-mass compounds has at best been poor. The water-in-oil microemulsion system as described in this review effectively overcomes the water-impermeable barrier of the epidermis and allows for effective delivery of highly water-soluble molecules such as peptides and proteins following topical application. Using this delivery formulation, high bioavailability of topically administered peptides and proteins, ranging from 900 Da molecular mass to > 150,000 Da molecular mass, has been achieved. Effective needle-free vaccine delivery has been achieved, as well as a new regime for weight loss, and the stimulation of anabolic activity in muscles has been achieved using topically delivered insulin, GHRP-6 and IGF-I. The studies presented add to earlier findings, which have shown effective delivery of monoclonal
antibodies and Fc-fusion proteins using topically applied water-in-oil microemulsions.

5. Expert opinion

The examples outlined in the preceding text do much to overcome many of the weaknesses in the field of topical delivery of peptides and proteins. In the past the general 'feeling' about delivery of peptides and proteins transdermally was that it would require some method of permeation enhancement or skin damage to achieve successful delivery. Even then the quantity of material delivered was small, and the molecular mass of the material delivered was generally low (< 6000 Da). Furthermore, the molecules delivered were generally hydrophobic, and the area of application was small. Transdermal delivery using water-in-oil microemulsions overcomes many of these problems. Thus, it is now possible to deliver large quantities of high-molecular-mass hydrophilic peptides or proteins using a vehicle that is well tolerated, does not cause mechanical disruption of the skin, and which can deliver material locally, regionally, or systemically.

This mode of delivery has enormous potential in many different areas of medicine, including vaccine delivery, topical delivery of therapeutic proteins, particularly molecules such as:

---

**Figure 4.** A. Variation in skin, muscle and visceral fat following subcutaneous (in saline) or transdermal (in water-in-oil microemulsion) administration of GHRP-6 (10 µg/dose), IGF-I (10 µg/dose) and insulin (10 µg/dose) (n = 5). B. Variation in visceral fat following subcutaneous (in saline) or transdermal (in water-in-oil microemulsion) administration of GHRP-6 (10 µg/dose), IGF-I (10 µg/dose) and insulin (10 µg/dose) (n = 5). Daily doses for 14 days.

s.c.: Subcutaneous; t.d.: Topical.
as anti-TNF, or TNF-Fc-fusion proteins for the treatment of inflammatory conditions such as psoriasis, rheumatoid arthritis, osteoarthritis, dermatitis, and so on, and imaging of sentinel lymph nodes, without the need for invasive surgery, which has particular relevance to the treatment of breast and skin cancer. Also, the prolonged profile of delivery using this route means that this mode of delivery has the potential to replace many of the depot delivery systems that are injected at present.

The major hurdle to transdermal delivery of proteins has thus been overcome with this mode of delivery, hence it has been demonstrated that it is possible to deliver pharmaceutically relevant doses of peptides and proteins using a vehicle that is pharmaceutically acceptable, cheap and easy to manufacture, and which is stable on storage. Foreseeable minor problems revolve around the stability of proteins when placed in solution. Thus, for some of the commercially available anti-TNF preparations, it was found that the proteins were not stable on reconstitution in buffer alone, presumably owing to the presence of small amounts of contaminating enzymes, which eventually degraded the protein. This was more a problem of the protein solution itself than the formulation into a water-in-oil microemulsion. Similarly, some proteins, such as human insulin utilized in the studies outlined above, tend to crystallize slowly on standing, particularly when stored at the concentration used in the microemulsions. This is a relatively minor formulation issue that can be overcome through the use of a different insulin analogue (Lispro, or insulin Aspart), or by means of slight modifications to the insulin formulation. This disadvantage is offset by the ability to deliver poorly water-soluble peptides and proteins, which can be made more readily solubilized by the dual water/oil formulation. Thus, many peptide antagonists are poorly water-soluble and must be injected in dispersing agents such as corn oil; these peptides are ideally suited for delivery in the much more acceptable water-in-oil formulation.

At present it is believed that most of the technical issues involved in formulation and delivery of peptides and proteins through the skin have been resolved. Continuing issues will therefore involve those usually associated with clinical trialing and registration with the relevant regulatory bodies, such as the Therapeutic Goods Administration (TGA) and FDA. There may also be some more hurdles owing to the change in bioactivity of the topically applied material when compared with already registered subcutaneously administered material, particularly in light of the different pharmacokinetic profiles and the difference in biological response observed with the altered pattern of distribution of the applied material (see Section 3.3).

Apart from the obvious advantages that will eventuate from needle-free injection of peptides and proteins, particularly exciting possibilities exist in true site-directed targeting of peptides and proteins for use in the many skin conditions that must at present use the subcutaneous route of administration. It is believed that much more effective

---

**Figure 5. Effect of administration of insulin formulated in saline and given subcutaneously, or formulated in a water-in-oil microemulsion and administered topically.** Female Swiss mice received formulations daily for 14 days, after which the mice were killed and their tissues dissected and weighed. Data are plotted as the change in body weight of the mice following treatment. Log-linear regression lines are plotted for with R^2 values. Control R^2 = 0.0843; insulin s.c. 10 µg R^2 = 0.2081; insulin t.d. 10 µg R^2 = 0.4543; insulin t.d. 30 µg R^2 = 0.7255; insulin t.d. 100 µg R^2 = 0.8254. The x-axis represents starting weight of mice (grams), the y-axis is the change in weight (grams).

s.c.: Subcutaneous; t.d.: Topical.
treatment will be achieved with far fewer side effects. Thus, there are many adverse side effects observed with continued subcutaneous administration of the many monoclonal antibodies now being developed or sold for the treatment of inflammation, the most serious sequela of this being death! Hopefully these adverse effects will be greatly reduced or even eliminated by topical delivery in water-in-oil microemulsions.

Perhaps even more benefit will be seen in the areas of breast and skin cancer, both for imaging of the primary lesion and the sentinel lymph nodes and also in the treatment of these insidious diseases. Thus, the lymph-seeking behavior of the water-in-oil microemulsion should be of particular benefit in the detection and treatment of both of these conditions.

In addition to the delivery of water-soluble proteins, the use of water and oil-soluble surfactants in the formation of the microemulsion has the extra advantage of being able to solubilize poorly soluble molecules \[83,84\]. For this reason, delivery of many hydrophobic molecules that have limited commercial utility, owing to delivery problems, will be able to achieve commercial reality through both the solubilizing power of the water-in-oil microemulsions as well as the transdermal delivery potential shown by such formulations. The biphasic nature of the water-in-oil microemulsion has the further advantage of being able to deliver both water and oil-soluble molecules simultaneously \[85,86\].

An exciting area of potential development is weight control management. The results using insulin, IGF-I and GHRP-6 given topically are particularly intriguing. Whether these results can be replicated in humans and whether the use of these drugs for potential treatment of obesity will be commercially viable will be particularly interesting to observe.

**Declaration of interest**

The authors declare no conflict of interest. G Russell-Jones is employed by Mentor Pharmaceutical Consulting Pty Ltd.

### Bibliography

25. Renkin EM, Wiig H. Limits to steady-state lymph flow rates derived from plasma-to-tissue uptake


41. Mills PC, Magnusson BM, Cross SE. The effects of vehicle and region of application on in vitro penetration of testosterone through canine skin. Vet J 2006;171:276-80


Water-in-oil microemulsions for effective transdermal delivery of proteins


78. Garvey WT, Olefsky JM, Marshall S. Insulin receptor down-regulation is associated with diminished insulin receptor autophosphorylation. Biochem J 1993;290:151-8


Affiliation
Gregory Russell-Jones1 & Roy Himes2
1Author for correspondence
1Mentor Pharmaceutical Consulting Pty Ltd, 23 Greenfield Ave, Middle Cove, Sydney, New South Wales 2069, Australia. Tel: +61 2 9417 6707; E-mail: mentor127@optusnet.com.au
2University of Wollongong, Northfields Ave, Wollongong, New South Wales 2522, Australia.